Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 47 | 2024 | 2931 | 6.900 |
Why?
|
Mouth Neoplasms | 15 | 2024 | 597 | 2.960 |
Why?
|
Carcinoma, Squamous Cell | 21 | 2024 | 4064 | 2.230 |
Why?
|
Immunotherapy | 18 | 2024 | 4756 | 1.390 |
Why?
|
Pyridones | 3 | 2021 | 819 | 1.320 |
Why?
|
Neoadjuvant Therapy | 12 | 2024 | 2909 | 1.310 |
Why?
|
Cancer Vaccines | 4 | 2021 | 1043 | 1.230 |
Why?
|
Pyrimidinones | 2 | 2021 | 386 | 1.060 |
Why?
|
Antigens, Neoplasm | 7 | 2021 | 2001 | 1.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 6 | 2022 | 1105 | 0.870 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2024 | 5342 | 0.870 |
Why?
|
CD8-Positive T-Lymphocytes | 13 | 2024 | 4651 | 0.820 |
Why?
|
Tumor Microenvironment | 14 | 2024 | 3952 | 0.810 |
Why?
|
Chordoma | 2 | 2017 | 349 | 0.710 |
Why?
|
Receptors, CXCR3 | 4 | 2011 | 240 | 0.660 |
Why?
|
Immunity, Cellular | 2 | 2019 | 1560 | 0.640 |
Why?
|
Oropharyngeal Neoplasms | 5 | 2023 | 493 | 0.630 |
Why?
|
Lymph Nodes | 3 | 2024 | 3473 | 0.590 |
Why?
|
Cell Line, Tumor | 20 | 2024 | 17173 | 0.530 |
Why?
|
Papillomavirus Infections | 6 | 2023 | 1640 | 0.520 |
Why?
|
Interferon-gamma | 4 | 2020 | 3163 | 0.490 |
Why?
|
Antigen Presentation | 1 | 2019 | 1252 | 0.450 |
Why?
|
Benzamides | 1 | 2019 | 1387 | 0.440 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2024 | 9442 | 0.430 |
Why?
|
Tumor Escape | 3 | 2012 | 372 | 0.430 |
Why?
|
Dendritic Cells | 2 | 2024 | 2748 | 0.430 |
Why?
|
Endoscopy | 4 | 2020 | 1862 | 0.420 |
Why?
|
Mice | 36 | 2024 | 82072 | 0.400 |
Why?
|
Indoles | 1 | 2019 | 1836 | 0.370 |
Why?
|
Cranial Nerve Neoplasms | 1 | 2011 | 134 | 0.340 |
Why?
|
T-Lymphocytes | 7 | 2024 | 10276 | 0.330 |
Why?
|
Mice, Inbred C57BL | 14 | 2024 | 22379 | 0.330 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 615 | 0.320 |
Why?
|
Free Tissue Flaps | 2 | 2024 | 337 | 0.310 |
Why?
|
Animals | 39 | 2024 | 169335 | 0.310 |
Why?
|
Disease Models, Animal | 8 | 2024 | 18354 | 0.310 |
Why?
|
Humans | 92 | 2024 | 768970 | 0.310 |
Why?
|
Neoplasm Regression, Spontaneous | 1 | 2008 | 47 | 0.300 |
Why?
|
Lymphocyte Subsets | 1 | 2008 | 313 | 0.280 |
Why?
|
Epigenesis, Genetic | 1 | 2021 | 3836 | 0.280 |
Why?
|
Protein Kinase Inhibitors | 4 | 2022 | 5707 | 0.270 |
Why?
|
Skull Base Neoplasms | 1 | 2009 | 281 | 0.250 |
Why?
|
Neurilemmoma | 1 | 2011 | 524 | 0.250 |
Why?
|
Receptors, Nerve Growth Factor | 2 | 2017 | 200 | 0.240 |
Why?
|
Chemokine CCL5 | 2 | 2024 | 214 | 0.240 |
Why?
|
Otitis Media with Effusion | 1 | 2005 | 115 | 0.230 |
Why?
|
DNA Mutational Analysis | 4 | 2021 | 4124 | 0.230 |
Why?
|
Neoplasms | 13 | 2024 | 22389 | 0.230 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2021 | 3671 | 0.230 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2024 | 8664 | 0.220 |
Why?
|
Islets of Langerhans Transplantation | 1 | 2008 | 748 | 0.210 |
Why?
|
Exodeoxyribonucleases | 1 | 2024 | 191 | 0.210 |
Why?
|
Papillomaviridae | 4 | 2023 | 1140 | 0.210 |
Why?
|
Osteoradionecrosis | 1 | 2022 | 51 | 0.200 |
Why?
|
Female | 39 | 2024 | 397515 | 0.200 |
Why?
|
Interferons | 3 | 2024 | 720 | 0.200 |
Why?
|
Carcinoma | 2 | 2023 | 2340 | 0.190 |
Why?
|
MAP Kinase Signaling System | 2 | 2021 | 1495 | 0.190 |
Why?
|
Antibodies, Monoclonal | 5 | 2019 | 9264 | 0.190 |
Why?
|
Lymphatic Metastasis | 4 | 2016 | 2916 | 0.190 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2011 | 2848 | 0.190 |
Why?
|
Granuloma, Plasma Cell | 1 | 2021 | 80 | 0.180 |
Why?
|
Biomarkers, Pharmacological | 1 | 2022 | 162 | 0.180 |
Why?
|
Hospitalization | 1 | 2020 | 10847 | 0.180 |
Why?
|
Surgical Flaps | 1 | 2009 | 1682 | 0.180 |
Why?
|
Vaccines, Subunit | 1 | 2021 | 159 | 0.180 |
Why?
|
Antineoplastic Agents | 1 | 2023 | 13698 | 0.180 |
Why?
|
Skin Neoplasms | 2 | 2011 | 5864 | 0.170 |
Why?
|
Immunologic Surveillance | 2 | 2012 | 93 | 0.170 |
Why?
|
GATA2 Transcription Factor | 1 | 2020 | 158 | 0.170 |
Why?
|
Receptors, Interferon | 2 | 2013 | 115 | 0.170 |
Why?
|
Vaccines, DNA | 1 | 2021 | 280 | 0.160 |
Why?
|
Mucin-1 | 1 | 2024 | 539 | 0.160 |
Why?
|
Interferon Type I | 1 | 2023 | 569 | 0.160 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 219 | 0.160 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2021 | 290 | 0.160 |
Why?
|
Pituitary Neoplasms | 3 | 2020 | 1326 | 0.160 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2021 | 3621 | 0.160 |
Why?
|
Histocompatibility Antigens Class II | 2 | 2021 | 1439 | 0.160 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2021 | 11886 | 0.160 |
Why?
|
Galectin 1 | 1 | 2019 | 128 | 0.160 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2023 | 701 | 0.160 |
Why?
|
Immunodominant Epitopes | 1 | 2019 | 244 | 0.160 |
Why?
|
DNA Probes | 1 | 2019 | 543 | 0.150 |
Why?
|
Neoplasm Invasiveness | 4 | 2017 | 3629 | 0.150 |
Why?
|
Middle Aged | 29 | 2024 | 223737 | 0.150 |
Why?
|
Gastroesophageal Reflux | 1 | 2005 | 836 | 0.150 |
Why?
|
Neoplasm Staging | 5 | 2024 | 11262 | 0.150 |
Why?
|
Gene Knockout Techniques | 1 | 2021 | 808 | 0.150 |
Why?
|
Male | 35 | 2024 | 365203 | 0.150 |
Why?
|
Aged, 80 and over | 14 | 2024 | 59739 | 0.140 |
Why?
|
Graft Survival | 1 | 2008 | 3888 | 0.140 |
Why?
|
Genes, Tumor Suppressor | 2 | 2018 | 1064 | 0.140 |
Why?
|
Aged | 24 | 2024 | 171786 | 0.140 |
Why?
|
Paranasal Sinuses | 1 | 2020 | 267 | 0.140 |
Why?
|
Endogenous Retroviruses | 1 | 2018 | 112 | 0.140 |
Why?
|
Triage | 1 | 2024 | 997 | 0.140 |
Why?
|
Molecular Sequence Annotation | 1 | 2019 | 527 | 0.140 |
Why?
|
Endothelium | 1 | 2019 | 768 | 0.140 |
Why?
|
Methylcholanthrene | 3 | 2012 | 30 | 0.140 |
Why?
|
Health Care Rationing | 1 | 2020 | 435 | 0.140 |
Why?
|
Receptor, erbB-3 | 1 | 2018 | 143 | 0.140 |
Why?
|
Precancerous Conditions | 1 | 2024 | 985 | 0.140 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2016 | 2063 | 0.140 |
Why?
|
Adult | 26 | 2024 | 223851 | 0.130 |
Why?
|
Killer Cells, Natural | 6 | 2024 | 2211 | 0.130 |
Why?
|
Dental Care | 1 | 2019 | 286 | 0.130 |
Why?
|
Morpholines | 1 | 2019 | 584 | 0.130 |
Why?
|
Qualitative Research | 2 | 2024 | 3143 | 0.130 |
Why?
|
DNA Polymerase II | 1 | 2016 | 104 | 0.130 |
Why?
|
Xanthogranuloma, Juvenile | 1 | 2015 | 16 | 0.130 |
Why?
|
Graft Rejection | 2 | 2008 | 4492 | 0.130 |
Why?
|
MAP Kinase Kinase 2 | 1 | 2015 | 93 | 0.130 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2022 | 812 | 0.130 |
Why?
|
Carotid Artery Injuries | 1 | 2016 | 96 | 0.120 |
Why?
|
Immunosuppressive Agents | 1 | 2008 | 4207 | 0.120 |
Why?
|
Transplantation, Isogeneic | 2 | 2012 | 249 | 0.120 |
Why?
|
Ethmoid Sinus | 1 | 2015 | 58 | 0.120 |
Why?
|
Sella Turcica | 1 | 2015 | 117 | 0.120 |
Why?
|
Phosphoproteins | 1 | 2024 | 2452 | 0.120 |
Why?
|
Surgery, Computer-Assisted | 1 | 2022 | 1006 | 0.120 |
Why?
|
Molecular Biology | 1 | 2018 | 573 | 0.120 |
Why?
|
Heart Transplantation | 1 | 2008 | 3301 | 0.120 |
Why?
|
Biphenyl Compounds | 1 | 2019 | 1026 | 0.110 |
Why?
|
Carcinosarcoma | 1 | 2015 | 108 | 0.110 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 4592 | 0.110 |
Why?
|
Mouth | 1 | 2016 | 383 | 0.110 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2015 | 331 | 0.110 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2021 | 4413 | 0.110 |
Why?
|
Biopsy | 3 | 2021 | 6805 | 0.110 |
Why?
|
Immunity, Innate | 2 | 2018 | 3080 | 0.110 |
Why?
|
Nerve Tissue Proteins | 2 | 2017 | 4413 | 0.110 |
Why?
|
Physical Examination | 1 | 2019 | 1262 | 0.110 |
Why?
|
Clinical Trials as Topic | 2 | 2021 | 8055 | 0.110 |
Why?
|
Carotid Artery, Internal | 1 | 2016 | 445 | 0.110 |
Why?
|
Survival Analysis | 5 | 2018 | 10115 | 0.100 |
Why?
|
Histones | 1 | 2023 | 2603 | 0.100 |
Why?
|
Nose Neoplasms | 1 | 2015 | 250 | 0.100 |
Why?
|
Paranasal Sinus Neoplasms | 1 | 2015 | 243 | 0.100 |
Why?
|
Genomics | 3 | 2023 | 5928 | 0.100 |
Why?
|
Histocompatibility Antigens Class I | 3 | 2018 | 1363 | 0.100 |
Why?
|
Molecular Targeted Therapy | 3 | 2019 | 2830 | 0.100 |
Why?
|
Listeriosis | 1 | 2013 | 147 | 0.100 |
Why?
|
Leukoplakia, Oral | 2 | 2024 | 79 | 0.100 |
Why?
|
Combined Modality Therapy | 3 | 2021 | 8559 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2018 | 2884 | 0.100 |
Why?
|
Immunophenotyping | 1 | 2017 | 1866 | 0.100 |
Why?
|
Teratoma | 1 | 2015 | 405 | 0.100 |
Why?
|
Cell Proliferation | 3 | 2019 | 10486 | 0.100 |
Why?
|
9,10-Dimethyl-1,2-benzanthracene | 1 | 2011 | 58 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2020 | 3554 | 0.100 |
Why?
|
Listeria monocytogenes | 1 | 2013 | 246 | 0.090 |
Why?
|
Cell Adhesion Molecules | 1 | 2018 | 1614 | 0.090 |
Why?
|
Immunologic Factors | 1 | 2021 | 1597 | 0.090 |
Why?
|
Prognosis | 7 | 2024 | 30046 | 0.090 |
Why?
|
Retrospective Studies | 12 | 2024 | 81903 | 0.090 |
Why?
|
Referral and Consultation | 1 | 2024 | 3628 | 0.090 |
Why?
|
T-Lymphocytes, Regulatory | 3 | 2012 | 3116 | 0.090 |
Why?
|
Skull | 1 | 2015 | 830 | 0.090 |
Why?
|
Interleukin-12 | 1 | 2013 | 577 | 0.090 |
Why?
|
Cell Cycle Proteins | 1 | 2022 | 3450 | 0.090 |
Why?
|
STAT1 Transcription Factor | 2 | 2024 | 343 | 0.090 |
Why?
|
Membrane Proteins | 2 | 2024 | 7885 | 0.090 |
Why?
|
Poly A-U | 1 | 2010 | 1 | 0.090 |
Why?
|
Disease-Free Survival | 3 | 2021 | 6856 | 0.090 |
Why?
|
Software | 2 | 2022 | 4479 | 0.090 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2011 | 826 | 0.090 |
Why?
|
Neoplasm Transplantation | 2 | 2012 | 2018 | 0.090 |
Why?
|
Patient Acceptance of Health Care | 1 | 2023 | 3235 | 0.080 |
Why?
|
Patient Selection | 2 | 2019 | 4265 | 0.080 |
Why?
|
Species Specificity | 1 | 2014 | 2417 | 0.080 |
Why?
|
Mice, Inbred BALB C | 4 | 2016 | 6232 | 0.080 |
Why?
|
Neoplasm Proteins | 2 | 2018 | 3608 | 0.080 |
Why?
|
Toll-Like Receptor 3 | 1 | 2010 | 99 | 0.080 |
Why?
|
Melanoma | 1 | 2008 | 5709 | 0.080 |
Why?
|
Palate, Soft | 1 | 2009 | 100 | 0.080 |
Why?
|
Vaccination | 1 | 2021 | 3438 | 0.080 |
Why?
|
Intraoperative Complications | 1 | 2016 | 1176 | 0.080 |
Why?
|
Cranial Fossa, Posterior | 1 | 2009 | 134 | 0.080 |
Why?
|
Immunomodulation | 1 | 2012 | 549 | 0.080 |
Why?
|
Epidermis | 1 | 2011 | 539 | 0.080 |
Why?
|
Mice, Mutant Strains | 1 | 2011 | 1755 | 0.070 |
Why?
|
Signal Transduction | 6 | 2024 | 23653 | 0.070 |
Why?
|
Chemotaxis, Leukocyte | 2 | 2008 | 660 | 0.070 |
Why?
|
Nuclear Proteins | 1 | 2022 | 5804 | 0.070 |
Why?
|
Maxillary Artery | 1 | 2007 | 18 | 0.070 |
Why?
|
Computational Biology | 1 | 2019 | 3562 | 0.070 |
Why?
|
Adaptive Immunity | 1 | 2012 | 733 | 0.070 |
Why?
|
Survivors | 1 | 2018 | 2383 | 0.070 |
Why?
|
S100 Proteins | 1 | 2008 | 217 | 0.070 |
Why?
|
Insurance, Health | 1 | 2019 | 2518 | 0.070 |
Why?
|
Disease Progression | 1 | 2024 | 13674 | 0.070 |
Why?
|
Forkhead Transcription Factors | 2 | 2012 | 1625 | 0.070 |
Why?
|
Genetic Variation | 2 | 2019 | 6611 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4919 | 0.070 |
Why?
|
Aneurysm, Infected | 1 | 2007 | 81 | 0.070 |
Why?
|
Sarcoma, Experimental | 1 | 2006 | 117 | 0.070 |
Why?
|
Melanoma, Experimental | 1 | 2010 | 559 | 0.070 |
Why?
|
Cohort Studies | 4 | 2024 | 41808 | 0.070 |
Why?
|
Neoplastic Stem Cells | 1 | 2014 | 1356 | 0.070 |
Why?
|
Sirolimus | 2 | 2015 | 1540 | 0.070 |
Why?
|
Pepsinogen A | 1 | 2005 | 14 | 0.060 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7460 | 0.060 |
Why?
|
DNA, Viral | 2 | 2023 | 2205 | 0.060 |
Why?
|
Immune Tolerance | 2 | 2019 | 2323 | 0.060 |
Why?
|
Pepsin A | 1 | 2005 | 64 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2014 | 3810 | 0.060 |
Why?
|
Adenoma | 1 | 2016 | 2163 | 0.060 |
Why?
|
Exudates and Transudates | 1 | 2005 | 175 | 0.060 |
Why?
|
DNA-Binding Proteins | 5 | 2018 | 9618 | 0.060 |
Why?
|
Glioma | 1 | 2020 | 3532 | 0.060 |
Why?
|
Cricetinae | 1 | 2008 | 2423 | 0.060 |
Why?
|
Middle Ear Ventilation | 1 | 2005 | 101 | 0.060 |
Why?
|
Mice, Nude | 3 | 2018 | 3631 | 0.060 |
Why?
|
Positron-Emission Tomography | 2 | 2022 | 6673 | 0.060 |
Why?
|
Aneurysm, False | 1 | 2007 | 263 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 4 | 2021 | 36854 | 0.060 |
Why?
|
Cell Differentiation | 1 | 2022 | 11684 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5434 | 0.060 |
Why?
|
Mutation | 4 | 2022 | 30266 | 0.060 |
Why?
|
Databases, Genetic | 2 | 2022 | 1758 | 0.050 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3421 | 0.050 |
Why?
|
Treatment Outcome | 4 | 2021 | 65480 | 0.050 |
Why?
|
Ear, Middle | 1 | 2005 | 341 | 0.050 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2022 | 2056 | 0.050 |
Why?
|
Neoplasm Metastasis | 3 | 2018 | 4926 | 0.050 |
Why?
|
Peptide Hydrolases | 1 | 2005 | 610 | 0.050 |
Why?
|
Sarcoma | 3 | 2012 | 1806 | 0.050 |
Why?
|
SOXB1 Transcription Factors | 1 | 2024 | 286 | 0.050 |
Why?
|
Transcription Factors | 1 | 2022 | 12174 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3118 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3241 | 0.050 |
Why?
|
Chemokines | 2 | 2023 | 963 | 0.050 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 1 | 2023 | 288 | 0.050 |
Why?
|
Models, Animal | 1 | 2008 | 2122 | 0.050 |
Why?
|
Endovascular Procedures | 1 | 2016 | 2218 | 0.050 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2023 | 332 | 0.050 |
Why?
|
5'-Nucleotidase | 1 | 2022 | 164 | 0.050 |
Why?
|
Glioblastoma | 1 | 2016 | 3525 | 0.050 |
Why?
|
Parotid Gland | 1 | 2022 | 178 | 0.050 |
Why?
|
Chemokines, CXC | 1 | 2002 | 420 | 0.050 |
Why?
|
Interferon-alpha | 1 | 2005 | 910 | 0.050 |
Why?
|
Phenotype | 3 | 2017 | 16731 | 0.050 |
Why?
|
T-Lymphocyte Subsets | 1 | 2008 | 1813 | 0.040 |
Why?
|
Neoplasms, Experimental | 1 | 2005 | 1231 | 0.040 |
Why?
|
Consensus | 2 | 2020 | 3214 | 0.040 |
Why?
|
Organs at Risk | 1 | 2022 | 368 | 0.040 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2018 | 5716 | 0.040 |
Why?
|
Receptors, Chemokine | 1 | 2002 | 652 | 0.040 |
Why?
|
Transplantation, Homologous | 1 | 2008 | 4835 | 0.040 |
Why?
|
Risk Assessment | 2 | 2012 | 24333 | 0.040 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2001 | 453 | 0.040 |
Why?
|
Software Design | 1 | 2019 | 173 | 0.040 |
Why?
|
Meningioma | 1 | 2008 | 1226 | 0.040 |
Why?
|
Meningeal Neoplasms | 1 | 2008 | 1258 | 0.040 |
Why?
|
Reoperation | 1 | 2009 | 4342 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2018 | 18068 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2021 | 15889 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2020 | 9213 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2022 | 567 | 0.040 |
Why?
|
Nasopharynx | 1 | 2021 | 420 | 0.040 |
Why?
|
RNA Splicing | 1 | 2023 | 905 | 0.040 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 3813 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2008 | 6320 | 0.040 |
Why?
|
RNA, Antisense | 1 | 2018 | 136 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2022 | 13594 | 0.040 |
Why?
|
Gene Amplification | 1 | 2022 | 1099 | 0.040 |
Why?
|
Alternative Splicing | 1 | 2023 | 1105 | 0.040 |
Why?
|
Cobalt | 1 | 2018 | 148 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2024 | 6086 | 0.040 |
Why?
|
Neuregulin-1 | 1 | 2018 | 136 | 0.030 |
Why?
|
Skull Base | 1 | 2020 | 294 | 0.030 |
Why?
|
Galectins | 1 | 2019 | 295 | 0.030 |
Why?
|
Gadolinium | 1 | 2021 | 965 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2024 | 2744 | 0.030 |
Why?
|
Prospective Studies | 4 | 2023 | 54962 | 0.030 |
Why?
|
Models, Immunological | 2 | 2012 | 518 | 0.030 |
Why?
|
Nose | 1 | 2020 | 524 | 0.030 |
Why?
|
Frameshift Mutation | 1 | 2018 | 393 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2022 | 9549 | 0.030 |
Why?
|
Quality of Life | 2 | 2024 | 13510 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2022 | 2921 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2021 | 1277 | 0.030 |
Why?
|
Sphenoid Bone | 1 | 2016 | 177 | 0.030 |
Why?
|
Genome | 1 | 2023 | 1754 | 0.030 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 1 | 2018 | 326 | 0.030 |
Why?
|
Leukocytes | 1 | 2002 | 2034 | 0.030 |
Why?
|
Cell Line | 1 | 2008 | 15604 | 0.030 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 283 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2008 | 11116 | 0.030 |
Why?
|
Lymphocyte Depletion | 1 | 2016 | 605 | 0.030 |
Why?
|
Mice, Knockout | 4 | 2013 | 14484 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 906 | 0.030 |
Why?
|
Gene Dosage | 1 | 2018 | 1222 | 0.030 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 627 | 0.030 |
Why?
|
Cell Growth Processes | 1 | 2014 | 381 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2023 | 1902 | 0.030 |
Why?
|
Algorithms | 3 | 2023 | 14201 | 0.030 |
Why?
|
Occupational Health | 1 | 2020 | 812 | 0.030 |
Why?
|
International Cooperation | 1 | 2020 | 1436 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2022 | 1970 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2008 | 12806 | 0.030 |
Why?
|
Cytokines | 1 | 2008 | 7453 | 0.030 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2022 | 1679 | 0.030 |
Why?
|
Recurrence | 1 | 2005 | 8513 | 0.030 |
Why?
|
Interleukin Receptor Common gamma Subunit | 1 | 2012 | 89 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2016 | 39394 | 0.030 |
Why?
|
Antigens, Ly | 1 | 2013 | 296 | 0.030 |
Why?
|
Tumor Burden | 1 | 2018 | 1913 | 0.030 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2016 | 1356 | 0.020 |
Why?
|
Drug Approval | 1 | 2019 | 821 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2022 | 2734 | 0.020 |
Why?
|
Nutrition Surveys | 1 | 2019 | 1738 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 2 | 2023 | 20776 | 0.020 |
Why?
|
ROC Curve | 1 | 2019 | 3629 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2022 | 22296 | 0.020 |
Why?
|
Fluorouracil | 1 | 2016 | 1655 | 0.020 |
Why?
|
Lymphocyte Activation | 2 | 2016 | 5505 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2019 | 1672 | 0.020 |
Why?
|
Young Adult | 4 | 2018 | 60131 | 0.020 |
Why?
|
Chronic Disease | 1 | 2005 | 9384 | 0.020 |
Why?
|
Chromatin | 1 | 2022 | 2981 | 0.020 |
Why?
|
Natural Killer T-Cells | 1 | 2013 | 318 | 0.020 |
Why?
|
Cisplatin | 1 | 2016 | 1661 | 0.020 |
Why?
|
Glucose | 1 | 2022 | 4352 | 0.020 |
Why?
|
Health Personnel | 1 | 2023 | 3383 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2022 | 3702 | 0.020 |
Why?
|
Interleukin-4 | 1 | 2013 | 1157 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2016 | 3102 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2018 | 2395 | 0.020 |
Why?
|
RNA Interference | 1 | 2018 | 2835 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2018 | 2460 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7214 | 0.020 |
Why?
|
Paclitaxel | 1 | 2016 | 1735 | 0.020 |
Why?
|
Proteins | 1 | 2023 | 6011 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2018 | 3433 | 0.020 |
Why?
|
Brain | 1 | 2015 | 27453 | 0.020 |
Why?
|
Contrast Media | 1 | 2021 | 5334 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2016 | 6131 | 0.020 |
Why?
|
Proteomics | 1 | 2022 | 3914 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2016 | 1887 | 0.020 |
Why?
|
Patient Discharge | 1 | 2021 | 3491 | 0.020 |
Why?
|
Cell Cycle | 1 | 2016 | 2937 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8748 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6547 | 0.020 |
Why?
|
Receptors, CCR5 | 1 | 2010 | 491 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2018 | 4785 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2018 | 20245 | 0.020 |
Why?
|
Length of Stay | 1 | 2021 | 6526 | 0.020 |
Why?
|
Societies, Medical | 1 | 2019 | 3968 | 0.020 |
Why?
|
Microfilament Proteins | 1 | 2012 | 1135 | 0.020 |
Why?
|
Time Factors | 1 | 2008 | 40261 | 0.020 |
Why?
|
Alcohol Drinking | 1 | 2019 | 4045 | 0.020 |
Why?
|
Ki-67 Antigen | 1 | 2008 | 628 | 0.020 |
Why?
|
Drug Synergism | 1 | 2010 | 1762 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7861 | 0.020 |
Why?
|
Radiation Chimera | 1 | 2005 | 216 | 0.020 |
Why?
|
Antigens, CD | 1 | 2015 | 4032 | 0.020 |
Why?
|
Computer Simulation | 1 | 2018 | 6291 | 0.020 |
Why?
|
Receptor, Interferon alpha-beta | 1 | 2005 | 113 | 0.010 |
Why?
|
Receptors, Interleukin-2 | 1 | 2006 | 564 | 0.010 |
Why?
|
Monitoring, Immunologic | 1 | 2005 | 100 | 0.010 |
Why?
|
Neurosurgical Procedures | 1 | 2016 | 2110 | 0.010 |
Why?
|
Logistic Models | 1 | 2019 | 13318 | 0.010 |
Why?
|
Cell Movement | 1 | 2016 | 5216 | 0.010 |
Why?
|
Radiography | 1 | 2015 | 6991 | 0.010 |
Why?
|
Genotype | 1 | 2018 | 13048 | 0.010 |
Why?
|
Phosphorylation | 1 | 2014 | 8317 | 0.010 |
Why?
|
Infant | 1 | 2005 | 36556 | 0.010 |
Why?
|
Adolescent | 2 | 2023 | 89244 | 0.010 |
Why?
|
Venules | 1 | 2002 | 161 | 0.010 |
Why?
|
Child, Preschool | 1 | 2005 | 42683 | 0.010 |
Why?
|
L-Selectin | 1 | 2002 | 212 | 0.010 |
Why?
|
Genes, p53 | 1 | 2005 | 716 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2013 | 4356 | 0.010 |
Why?
|
Skin | 1 | 2015 | 4506 | 0.010 |
Why?
|
Survival Rate | 1 | 2016 | 12873 | 0.010 |
Why?
|
Contig Mapping | 1 | 2001 | 56 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2015 | 12095 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26395 | 0.010 |
Why?
|
United States | 2 | 2019 | 73186 | 0.010 |
Why?
|
Expressed Sequence Tags | 1 | 2001 | 251 | 0.010 |
Why?
|
Chemokine CXCL12 | 1 | 2002 | 457 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8749 | 0.010 |
Why?
|
Apoptosis | 1 | 2016 | 9527 | 0.010 |
Why?
|
Blotting, Northern | 1 | 2001 | 1553 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2018 | 16053 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2012 | 4939 | 0.010 |
Why?
|
Conserved Sequence | 1 | 2001 | 1162 | 0.010 |
Why?
|
Receptors, CXCR4 | 1 | 2002 | 729 | 0.010 |
Why?
|
Macrophages | 1 | 2012 | 5801 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2010 | 9565 | 0.010 |
Why?
|
Child | 1 | 2005 | 80960 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2001 | 2749 | 0.010 |
Why?
|
Lymphocytes | 1 | 2005 | 2614 | 0.010 |
Why?
|
Homozygote | 1 | 2001 | 1780 | 0.010 |
Why?
|
Hematopoiesis | 1 | 2005 | 2059 | 0.010 |
Why?
|
Ligands | 1 | 2002 | 3283 | 0.010 |
Why?
|
Exons | 1 | 2001 | 2395 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2005 | 2960 | 0.010 |
Why?
|
Protein Biosynthesis | 1 | 2001 | 2094 | 0.010 |
Why?
|
Inflammation Mediators | 1 | 2002 | 1890 | 0.010 |
Why?
|
Gene Deletion | 1 | 2001 | 2674 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2007 | 4076 | 0.010 |
Why?
|
Risk Factors | 1 | 2019 | 74976 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2007 | 13021 | 0.010 |
Why?
|
Models, Genetic | 1 | 2001 | 3449 | 0.010 |
Why?
|
Alleles | 1 | 2001 | 6901 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2001 | 13427 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2001 | 17629 | 0.000 |
Why?
|
Transcription, Genetic | 1 | 2001 | 7609 | 0.000 |
Why?
|
Breast Neoplasms | 1 | 2010 | 21188 | 0.000 |
Why?
|